A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
收藏DataCite Commons2025-10-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00007118/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is 2-fold: initially, in the dose escalation phase, the goal is to
determine the safety profile of orally administered brigatinib, including: the maximum
tolerated dose (MTD), dose limiting toxicities (DLTs), recommended phase 2 dose (RP2D), and
pharmacokinetic (PK) profile. Then, once the RP2D is established, an expansion phase will
assess the preliminary anti-tumor activity of brigatinib, both in non-small cell lung cancer
(NSCLC) with ALK gene rearrangement (including participants with active brain metastases) or
mutated EGFR, and in other cancers with abnormal targets against which brigatinib is active.
提供机构：
Vivli
创建时间：
2021-05-06
